AU747012B2 - Preparation of thioarabinofuranosyl compounds and use thereof - Google Patents

Preparation of thioarabinofuranosyl compounds and use thereof Download PDF

Info

Publication number
AU747012B2
AU747012B2 AU51239/99A AU5123999A AU747012B2 AU 747012 B2 AU747012 B2 AU 747012B2 AU 51239/99 A AU51239/99 A AU 51239/99A AU 5123999 A AU5123999 A AU 5123999A AU 747012 B2 AU747012 B2 AU 747012B2
Authority
AU
Australia
Prior art keywords
compound
thio
group
arac
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU51239/99A
Other languages
English (en)
Other versions
AU5123999A (en
Inventor
John A. Montgomery
John A. Secrist Iii
Kamal N. Tiwari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Research Institute
Original Assignee
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Research Institute filed Critical Southern Research Institute
Publication of AU5123999A publication Critical patent/AU5123999A/en
Application granted granted Critical
Publication of AU747012B2 publication Critical patent/AU747012B2/en
Priority to AU2002300586A priority Critical patent/AU2002300586B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU51239/99A 1998-07-23 1999-07-23 Preparation of thioarabinofuranosyl compounds and use thereof Expired AU747012B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002300586A AU2002300586B2 (en) 1998-07-23 2002-08-09 A method for treating solid tumors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9386998P 1998-07-23 1998-07-23
US60/093869 1998-07-23
PCT/US1999/016630 WO2000004866A2 (en) 1998-07-23 1999-07-23 Preparation of thioarabinofuranosyl compounds and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2002300586A Division AU2002300586B2 (en) 1998-07-23 2002-08-09 A method for treating solid tumors

Publications (2)

Publication Number Publication Date
AU5123999A AU5123999A (en) 2000-02-14
AU747012B2 true AU747012B2 (en) 2002-05-09

Family

ID=22241386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU51239/99A Expired AU747012B2 (en) 1998-07-23 1999-07-23 Preparation of thioarabinofuranosyl compounds and use thereof

Country Status (9)

Country Link
US (5) US6576621B1 (enExample)
EP (3) EP2332551B1 (enExample)
JP (3) JP4719356B2 (enExample)
AT (1) ATE531376T1 (enExample)
AU (1) AU747012B2 (enExample)
CA (1) CA2338415C (enExample)
ES (3) ES2402799T3 (enExample)
NZ (1) NZ509405A (enExample)
WO (1) WO2000004866A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ509405A (en) * 1998-07-23 2004-10-29 Southern Res Inst Preparation of 1-(4-thio-thioarabinofuranosyl) cytosine derivatives and their use as anticancer agents and DNA replication inhibitors
US20060127990A1 (en) * 2002-08-22 2006-06-15 Geneticlab Co., Ltd 4'-thionucleotide
US7524831B2 (en) * 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
EP2124553B1 (en) * 2007-03-23 2017-03-01 Southern Research Institute Method for treating and preventing arthritis
AR064165A1 (es) 2007-12-06 2009-03-18 Richmond Sa Com Ind Y Financie Un procedimiento para la preparacion de capecitabina e intermediarios utilizables en dicho procedimiento
WO2009158412A2 (en) * 2008-06-25 2009-12-30 Endo Pharmaceuticals Solutions Inc. Sustained delivery of exenatide and other polypeptides
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
SG10201603288XA (en) 2012-03-28 2016-05-30 Fujifilm Corp Salt Of 1-(2-Deoxy-2-Fluoro-4-Thio-beta-D-Arabinofuranosyl)Cytosine
JP6175553B2 (ja) 2014-02-18 2017-08-09 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6351107B2 (ja) * 2014-02-18 2018-07-04 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
JP6245527B2 (ja) * 2014-03-24 2017-12-13 富士フイルム株式会社 チオラン環もしくはチアン環骨格を有する化合物の製造方法
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
HK1252245A1 (zh) * 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
WO2017091836A1 (en) * 2015-11-25 2017-06-01 University Of South Carolina Enhancement of cytarabine activity by inhibiting cdk8/19
BR112019003946A2 (pt) 2016-08-31 2019-05-21 Fujifilm Corporation agente antitumoral, reforçador do efeito antitumoral e kit antitumoral
MX2018002611A (es) 2018-01-29 2019-07-30 Fujifilm Corp Agente antitumoral para cancer del tracto biliar y metodo para tratar cancer del tracto biliar.
AU2019256465B2 (en) * 2018-04-19 2024-10-03 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
JP2022535849A (ja) * 2019-06-05 2022-08-10 サウザーン リサーチ インスチチュート チアラビンベースおよびチアラビンのプロドラッグベースの治療
CA3176543A1 (en) 2020-04-23 2021-10-28 Mark J. Suto Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491793B1 (en) * 1989-09-15 2005-11-30 Southern Research Institute 2'-deoxy-4'-thioribonucleosides as antiviral and anticancer agents
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
AU639973B2 (en) * 1989-12-08 1993-08-12 City Of Hope Circumvention of human tumor drug resistance
JPH0925289A (ja) 1995-07-14 1997-01-28 Yamasa Shoyu Co Ltd ４’−チオアラビノピリミジンヌクレオシドの製造方法
JPH09249690A (ja) 1995-07-14 1997-09-22 Yamasa Shoyu Co Ltd ４’−チオアラビノプリンヌクレオシド
JP2943690B2 (ja) 1996-04-17 1999-08-30 日本電気株式会社 セル衝突検出装置
JP2001525667A (ja) 1997-05-09 2001-12-11 リボザイム・ファーマシューティカルズ・インコーポレーテッド Ｃ−ｒａｆの発現レベルに関係した疾患または状態の酵素核酸処置
US6548657B1 (en) * 1997-06-09 2003-04-15 Ribozyme Pharmaceuticals, Inc. Method for screening nucleic acid catalysts
WO1999043690A1 (en) 1998-02-25 1999-09-02 Rational Drug Design Laboratories L-4'-arabinofuranonucleoside compound and medicine composition comprising the same
NZ509405A (en) * 1998-07-23 2004-10-29 Southern Res Inst Preparation of 1-(4-thio-thioarabinofuranosyl) cytosine derivatives and their use as anticancer agents and DNA replication inhibitors

Also Published As

Publication number Publication date
WO2000004866A3 (en) 2000-04-20
ES2376862T3 (es) 2012-03-20
WO2000004866A9 (en) 2000-08-10
US20050038025A1 (en) 2005-02-17
US6870052B2 (en) 2005-03-22
ES2402799T3 (es) 2013-05-09
US7138385B2 (en) 2006-11-21
JP2010202655A (ja) 2010-09-16
EP1100512A4 (en) 2001-10-10
EP2332551A1 (en) 2011-06-15
US6576621B1 (en) 2003-06-10
JP4719356B2 (ja) 2011-07-06
EP1100512B1 (en) 2011-11-02
EP2332551B1 (en) 2013-01-09
AU5123999A (en) 2000-02-14
CA2338415C (en) 2006-10-10
EP2335706B1 (en) 2013-10-23
NZ509405A (en) 2004-10-29
US20100216797A1 (en) 2010-08-26
JP5357857B2 (ja) 2013-12-04
EP2335706A1 (en) 2011-06-22
US20060287320A1 (en) 2006-12-21
JP2011032281A (ja) 2011-02-17
ES2438144T3 (es) 2014-01-16
US8178510B2 (en) 2012-05-15
CA2338415A1 (en) 2000-02-03
US7691820B2 (en) 2010-04-06
JP2002521318A (ja) 2002-07-16
US20030203872A1 (en) 2003-10-30
EP1100512A2 (en) 2001-05-23
WO2000004866A2 (en) 2000-02-03
ATE531376T1 (de) 2011-11-15

Similar Documents

Publication Publication Date Title
US8178510B2 (en) Preparation of thioarabinofuranosyl compounds and use thereof
KR20140023913A (ko) 암 치료에 사용하기 위한 5-플루오로-2''-데옥시우리딘의 포스포르아미데이트 유도체
JPH05506240A (ja) ５―ベンジルバルビツレート誘導体
ES2329428T3 (es) Derivados de 5'-deoxi-citidina.
EP2986120B1 (en) Methyltransferase inhibitors for treating cancer
WO1999012951A1 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
EP0788495A2 (en) L-erythrosyl nucleosides
EP0788507B1 (en) L-pyranosyl nucleosides
GB1570555A (en) Anti-cancer composition
AU2002300586B2 (en) A method for treating solid tumors
CA2707593A1 (en) Clofarabine phospholipid derivatives
CA2464681C (en) Preparation of thioarabinofuranosyl compounds and use thereof
JP2784941B2 (ja) ２’‐メチリデンピリミジンヌクレオシド化合物およびその医薬用途
WO2002098397A2 (en) Therapeutic compositions for modulating the immune response in a mammal and use thereof
CA2203674A1 (en) L-pyranosyl nucleosides
MXPA97010529A (es) Compuestos terapeuticos
CA2203672A1 (en) L-ribofuranosyl nucleosides
CA2203675A1 (en) L-erythrosyl nucleosides
HK1016991A (en) 5'-deoxy-cytidine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired